{
    "Trade/Device Name(s)": [
        "Elecsys PTH",
        "Elecsys PTH STAT"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K231927",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070709"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "March 22, 2024",
    "Summary Letter Received Date": "February 22, 2024",
    "Submission Date": "March 11, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid Hormone Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Intact parathyroid hormone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas e immunoassay analyzers",
        "Elecsys immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Diagnostics Elecsys PTH and Elecsys PTH STAT immunoassays for the quantitative determination of intact parathyroid hormone using ECLIA on cobas e/Elecsys analyzers.",
    "Indications for Use Summary": "Immunoassay for in vitro quantitative determination of intact parathyroid hormone in human serum and plasma for the differential diagnosis of hypercalcemia and hypocalcemia, usable intraoperatively on cobas e immunoassay analyzers.",
    "fda_folder": "Clinical Chemistry"
}